1 xicity comparable to that of matched-sibling
donor leukocyte infusion.
2 recipients treated with DNA vaccination and
donor leukocyte infusion.
3 mmarizes recent data on the use of unrelated-
donor leukocyte infusion.
4 cutaneous graft-versus-host disease, without
donor leukocyte infusion.
5 lapse after allogeneic transplantation using
donor leukocyte infusions.
6 Donor leukocyte infusions (
1x10(7) /kg CD3+ T cells) wer
7 Extensive data are available on the use of
donor leukocyte infusion after matched-sibling stem cell
8 but reports are remarkably few on the use of
donor leukocyte infusion after unrelated-donor stem cell
9 Donor leukocyte infusions after allogeneic bone marrow t
10 eneic peripheral blood cell transplantation,
donor leukocyte infusions,
and unrelated bone marrow tra
11 Donor leukocyte infusion (
DLI) can induce graft-versus-l
12 In mice,
donor leukocyte infusion (
DLI) given to established mixe
13 r role in another model involving delayed B6
donor leukocyte infusion (
DLI) to established mixed allo
14 A disease response to
donor leukocyte infusion (
DLI) was seen in 10 of 14 pati
15 ents achieved complete donor chimerism after
donor leukocyte infusion (
DLI).
16 l transplantation (alloHSCT) can be cured by
donor leukocyte infusion (
DLI); however, the cellular me
17 The efficacy and toxicity of
donor leukocyte infusions (
DLI) after unrelated donor bo
18 Therapy of recurrent disease with
donor leukocyte infusions (
DLI) has been proven to be ef
19 Donor leukocyte infusions (
DLI) in the allogeneic hemato
20 Adoptive immunotherapy with
donor leukocyte infusions (
DLI) results in complete remi
21 effect has been provided by the efficacy of
donor leukocyte infusions (
DLI).
22 y alone, second myeloablative transplant, or
donor leukocyte infusions (
DLIs) alone is unusual.
23 We evaluated HLA-compatible
donor leukocyte infusions (
DLIs) and HLA-compatible or H
24 llowing bone marrow transplantation, delayed
donor leukocyte infusions (
DLIs) can induce graft-versus
25 Histocompatible allogeneic
donor leukocyte infusions (
DLIs) were administered as pr
26 together with the known antitumor effects of
donor leukocyte infusions (
DLIs), led to the design of t
27 In vitro analysis of splenocytes from
donor leukocyte infusion donor mice demonstrated that im
28 Several case studies suggest that unrelated-
donor leukocyte infusion effectively induces direct graf
29 ive allogeneic stem cell transplantation and
donor leukocyte infusion for the induction of graft vers
30 In this murine system,
donor leukocyte infusion from a donor immunized with the
31 Donor leukocyte infusion further enhances tumor-free sur
32 nsplantation has led to the use of unrelated-
donor leukocyte infusion in many patients.
33 There is a paucity of data on unrelated-
donor leukocyte infusion in this setting.
34 But the role for unrelated-
donor leukocyte infusion is not well established.
35 Expression of MHC class I on
donor leukocyte infusions is important for overcoming re
36 Donor leukocyte infusions provide direct and potent graf
37 d transplant and three of three who received
donor leukocyte infusions)
remain alive.
38 The dramatic success of
donor leukocyte infusion to treat relapse after matched-
39 The effects of posttransplant
donor leukocyte infusions to treat or prevent cytomegalo
40 Apoptotic
donor leukocyte infusions warrant continued investigatio